Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Acromegaly-associated diabetes raises cardiovascular risk more than type 2 diabetes alone. A large Swedish cohort study found patients with this rare condition faced significantly higher rates of venous thromboembolism, pulmonary embolism, and arrhythmia. Researchers say aggressive management of hypertension and other modifiable risk factors is key to reducing the cardiovascular toll in this population.
Patients who develop diabetes as a complication of acromegaly — a condition caused by excess growth hormone — face a notably higher cardiovascular burden than those with standard type 2 diabetes (T2D), according to a new nationwide Swedish cohort study published in The Journal of Clinical Endocrinology & Metabolism.
The study matched 348 patients with acromegaly-associated diabetes against 3,480 T2D controls over roughly nine years. Cardiovascular disease was far more prevalent in the acromegaly group (61% vs. 43%), with higher rates of hypertension, heart failure, arrhythmia, and stroke — though overall cardiovascular mortality was similar between groups.
By the Numbers:
Why it matters: Acromegaly is rare, but its metabolic complications are serious. This study highlights that diabetes in acromegaly patients isn't just "regular" T2D — it carries a distinct and elevated cardiovascular risk profile that warrants more vigilant monitoring and tailored treatment strategies.
